Final answer:
Bevacizumab, a common treatment for metastatic colorectal cancer, can have adverse effects such as hypertension and increased bleeding risk. Close monitoring and supportive care are essential when these complications arise.
Step-by-step explanation:
When it comes to the treatment of metastatic colorectal cancer with bacizumab, which I believe could be a typo for bevacizumab (a more commonly known medication for this type of cancer), there are several potential adverse effects to consider. Bevacizumab works by inhibiting the growth of blood vessels that feed tumors, but it can also affect normal cells, leading to complications.
Some known adverse effects of bevacizumab include hypertension, increased risk of bleeding and hemorrhage, proteinuria, and gastrointestinal perforation among others. Proper management requires close monitoring by healthcare providers, and supportive care may include antihypertensive medication for blood pressure control or pharmacological interventions for bleeding. Additionally, in case of an adverse reaction, treatment with bevacizumab may need to be paused or discontinued, following a specialist’s advice.